Literature DB >> 31156159

O-GlcNAcylation of Amyloid-β Protein Precursor by Insulin Signaling Reduces Amyloid-β Production.

Oh Hoon Kwon1, Yoon Young Cho1, Tae-Wan Kim2, Sungkwon Chung1.   

Abstract

Alzheimer's disease (AD) is caused by the accumulation of neurotoxic amyloid-β (Aβ) peptides. Aβ is derived from amyloid-β protein precursor (AβPP). In the non-amyloidogenic pathway, AβPP is cleaved by α-secretase and γ-secretase at the plasma membrane, excluding Aβ production. Alternatively, AβPP in the plasma membrane is internalized via endocytosis, and delivered to early endosomes and lysosomes, where it is cleaved by β-secretase and γ-secretase. Recent studies have shown that insulin in the periphery crosses the blood-brain barrier, and plays important roles in the brain. Furthermore, impaired insulin signaling has been linked to the progression of AD, and intranasal insulin administration improves memory impairments and cognition. However, the underlying molecular mechanisms of insulin treatment remain largely unknown. To investigate the effects of insulin on AβPP processing, we tested the effects of insulin on neuroblastoma SH-SY5Y cells overexpressing AβPP, and cultured rat cortical neurons. We found that insulin increased the level of cell surface AβPP, decreasing the endocytosis rate of AβPP. Insulin reduced Aβ generation through upregulation of AβPP O-GlcNAcylation via Akt insulin signaling. Our present data suggest that insulin affects Aβ production by regulating AβPP processing through AβPP O-GlcNAcylation. These results provide mechanistic insight into the beneficial effects of insulin, and a possible link between insulin deficient diabetes and cerebral amyloidosis in the pathogenesis of AD.

Entities:  

Keywords:  Alzheimer’s disease; O-GlcNAcylation; amyloid-βzzm321990; amyloid-β protein zzm321990precursor; insulin

Year:  2019        PMID: 31156159     DOI: 10.3233/JAD-190060

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function.

Authors:  Zoe Arvanitakis; Hoau-Yan Wang; Ana W Capuano; Amber Khan; Bouchra Taïb; Frederick Anokye-Danso; Julie A Schneider; David A Bennett; Rexford S Ahima; Steven E Arnold
Journal:  Ann Neurol       Date:  2020-07-27       Impact factor: 10.422

Review 2.  Intranasal Insulin for Alzheimer's Disease.

Authors:  Manfred Hallschmid
Journal:  CNS Drugs       Date:  2021-01-30       Impact factor: 5.749

Review 3.  Neuroprotective Potentials of Panax Ginseng Against Alzheimer's Disease: A Review of Preclinical and Clinical Evidences.

Authors:  Jing Li; Qingxia Huang; Jinjin Chen; Hongyu Qi; Jiaqi Liu; Zhaoqiang Chen; Daqing Zhao; Zeyu Wang; Xiangyan Li
Journal:  Front Pharmacol       Date:  2021-06-02       Impact factor: 5.810

4.  Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer's disease.

Authors:  Claudia P Boix; Inmaculada Lopez-Font; Inmaculada Cuchillo-Ibañez; Javier Sáez-Valero
Journal:  Alzheimers Res Ther       Date:  2020-08-12       Impact factor: 6.982

5.  O-GlcNAcylation Inhibits Endocytosis of Amyloid Precursor Protein by Decreasing Its Localization in Lipid Raft Microdomains.

Authors:  Oh-Hoon Kwon; Yoon Young Cho; Jung Hee Lee; Sungkwon Chung
Journal:  Membranes (Basel)       Date:  2021-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.